Search
avelumab (Bavencio)
Indications:
- metastatic Merkel cell carcinoma
- advanced urothelial carcinoma with disease progression after platinum-based chemotherapy [4]
Dosage:
- 10 mg/kg IV every 2 weeks
- continue until disease progression or unacceptable toxicity
Adverse effects:
- most common
- fatigue, musculoskeletal pain
- diarrhea, nausea, decreased appetite
- infusion-related reactions, rash
- peripheral edema
- serious adverse effects
- immune-mediated effects.
Mechanism of action:
- PD-L1 inhibitor
Interactions
drug adverse effects of checkpoint inhibitor(s)
General
checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
antineoplastic monoclonal antibody
References
- Bankhead C
FDA Approves Drug for Rare Skin Cancer.
- Avelumab active in Merkel cell carcinoma.
MedPage Today. March 23, 2017
https://www.medpagetoday.com/Dermatology/SkinCancer/64096
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Kaufman HL, Russell J, Hamid O et al
Avelumab in patients with chemotherapy-refractory metastatic
Merkel cell carcinoma: a multicentre, single-group, open-label,
phase 2 trial.
Lancet Oncol. 2016 Oct;17(10):1374-1385. Epub 2016 Sep 1.
PMID: 27592805 Free PMC Article
- Apolo AB, Infante JR, Balmanoukian A et al
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In
Patients With Refractory Metastatic Urothelial Carcinoma:
Results From a Multicenter, Phase Ib Study.
J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4.
PMID: 28375787 Free Article
- Powles T et al.
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.
N Engl J Med 2020 Sep 18; [e-pub]
PMID: 32945632
https://www.nejm.org/doi/10.1056/NEJMoa2002788